Multiple Tumor Types TAPUR

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

Eligibility Criteria:

  • Patient with a histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma
  • No longer benefitting from standard anti-cancer treatment
  • Disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma)
  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression

This study is for patients age 18 and older.

Available at: Hartford Hospital, Hospital of Central Connecticut, Midstate Medical Center, William Backus Hospital, Windham Hospital, Charlotte Hungerford Hospital, St. Vincent's Medical Center.

Cancer Clinical Research Office